Figure 7

Pancreatic sections of healthy non-diabetic groups (HGI to HGVII) and diabetic groups treated with free Mel (10 mg/kg, DGIII) or Mel-C/L nanoparticles (5 or 10 mg/kg; DGVI or DGVII) showing average-sized pale-staining islets of Langerhans (black arrow) (A,D,F,G; H&E X200), positive immunostain for insulin (yellow arrow) (H,J,L; X200) and negative immunosatin for NF-κB (M,R; X200); pancreatic sections of untreated diabetic group (DGI) and diabetic groups treated with free Mel (5 mg/kg, DGII) or unloaded C/L nanoparticles (5 or 10 mg/kg; DGIV or DGV) showing few small-sized hypocellular pale-staining islets of Langerhans with scattered apoptotic β cells and markedly edematous cytoplasm (red arrow) (B,C,E; H&E X200), negative immunostain for insulin (blue arrow) (I,K; X200), and positive immunostain for NF-B (N,O,P,Q; X200). HGI Control untreated rats, HGII Healthy rats that received free Mel (5 mg/kg), HGIII Healthy rats that received free Mel (10 mg/kg), HGIV Healthy rats that received unloaded C/L nanoparticles (5 mg/kg), HGV Healthy rats that received unloaded C/L nanoparticles (10 mg/kg), HGVI Healthy rats that received Mel-C/L nanoparticles (5 mg/kg), HGVII Healthy rats that received Mel-C/L nanoparticles (10 mg/kg), DGI Control untreated rats, DGII Diabetic rats that received free Mel (5 mg/kg), DGIII Diabetic rats that received free Mel (10 mg/kg), DGIV Diabetic rats that received unloaded C/L nanoparticles (5 mg/kg), DGV Diabetic rats that received unloaded C/L nanoparticles (10 mg/kg), DGVI Diabetic rats that received Mel-C/L nanoparticles (5 mg/kg), DGVII Diabetic rats that received Mel-C/L nanoparticles (10 mg/kg).